November 2021 - PsychedelicNewsWire (PNW)

TuesdayNov 30, 2021 3:00 pm

Psychedelics Firms Race to Shorten Therapeutic Trips’ Duration

Research on psychedelics has grown tremendously these past few years, as more about potential health benefits are discovered. For instance, substances such as psilocybin and MDMA have shown potential in the treatment of various conditions, including post-traumatic stress disorder and depression. Some research has shown that these substances may be even more effective than current treatments for these conditions, which can take weeks to begin working. The primary downside of these substances is the duration of psychedelic trips, which drug=development and biotech companies are working to make shorter. Normally, psychedelic trips range between 4 to 12 hours, depending on the…

MondayNov 29, 2021 2:00 pm

Study Finds That Use of Psychedelics Decreases Opioid Consumption

New research has found that the use of psychedelic substances such as DMT, mescaline, psilocybin and LSD is linked to a considerable decline in the consumption of opioids. For their study, the researchers analyzed data from cohorts comprised of individuals suffering from substance misuse disorders. These cohorts included more than 200 people who admitted to using psychedelic substances in the last six months while another 1,092 admitted to using opioids. The researchers found that using psychedelics was linked to a 55% decrease in the daily use of opioids. Their findings were published in the “Journal of International Drug Policy.” It…

MondayNov 29, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders There is no denying that food is a…

WednesdayNov 24, 2021 12:30 pm

Psilocybin Mushroom Measure May Make Pennsylvania New Psychedelic Research Hub

The state of Pennsylvania may become the new psychedelic research hub in the United States if a measure that was introduced in the state’s House of Representatives in October is approved. The measure, dubbed the Public Health Benefits of Psilocybin Act, will establish a framework for research on psilocybin to be conducted in order to determine its effectiveness as a treatment for various mental health conditions. Psilocybin is the active compound found in hallucinogenic mushrooms. The Health Committee will be voting on the initiative this coming week. The prime sponsor of the measure is Tracy Pennycuick, an army veteran. It…

TuesdayNov 23, 2021 12:00 pm

Study Finds Psilocybin Improves Neural, Cognitive Flexibility in Patients with Depression

A new study has found that psilocybin-assisted psychotherapy increases neural and cognitive flexibility in patients suffering from major depressive disorder. Psilocybin is the active compound found in hallucinogenic mushrooms. Research has found that the component has clinically substantial and long-lasting effects on mood and personality when used in conjunction with psychotherapy. The study was published in “Translational Psychiatry,” with researchers suggesting that psychedelic-induced increases in neural flexibility don’t always translate into cognitive improvements. The study’s authors were focused on assessing the effects of psilocybin on neural flexibility, which refers to variability in brain connectivity and activity, and cognitive flexibility, which…

MondayNov 22, 2021 1:15 pm

Psilocybin Could Help Address Attachment Anxiety

Researchers are exploring whether psilocybin can be used to help individuals who feel insecure in their attachments to other people. Their findings suggest that psilocybin-assisted psychotherapy may help decrease attachment anxiety. Individuals can be insecure or secure in their attachments, with those who are insecure being either avoidant or anxious. Individuals with an avoidant style of attachment may shun intimacy and distrust other people while those with an anxious style of attachment tend to be fearful of abandonment and rejection. Researchers believe that while these styles of attachment are usually relatively stable, they may change over time. Christopher S. Stauffer,…

MondayNov 22, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September…

MondayNov 22, 2021 8:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations Tryp…

FridayNov 19, 2021 1:30 pm

DEA Announces New Production Quotas for Psychedelic Substances for 2021, 2022

The DEA announced in September that it would be increasing the production quotas for Schedule I substances such as DMT, MDMA and psilocybin. This was after revealing the agency’s objective to produce more psychedelic substances for purposes of research next year. By the end of 2021, the DEA wants 6,000 grams of psilocybin to be manufactured, which is four times its last production quota. In its proposal, the agency states that the production quota for DMT and MDMA will be increased to 3,200 grams from 50 grams each. It also wants 2 million grams of cannabis to be produced this…

FridayNov 19, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: November 2021